Theravance Total Current Liabilities from 2010 to 2024

TBPH Stock  USD 8.98  0.35  4.06%   
Theravance Biopharma's Total Current Liabilities is increasing with stable movements from year to year. Total Current Liabilities is predicted to flatten to about 23.5 M. Total Current Liabilities is the total amount of liabilities that Theravance Biopharma is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. View All Fundamentals
 
Total Current Liabilities  
First Reported
2012-12-31
Previous Quarter
24.8 M
Current Value
21.7 M
Quarterly Volatility
34.5 M
 
Yuan Drop
 
Covid
Check Theravance Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theravance Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4 M, Interest Expense of 2.2 M or Total Revenue of 56.6 M, as well as many indicators such as Price To Sales Ratio of 10.28, Dividend Yield of 0.0 or PTB Ratio of 3.06. Theravance financial statements analysis is a perfect complement when working with Theravance Biopharma Valuation or Volatility modules.
  
Check out the analysis of Theravance Biopharma Correlation against competitors.
For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.

Latest Theravance Biopharma's Total Current Liabilities Growth Pattern

Below is the plot of the Total Current Liabilities of Theravance Biopharma over the last few years. Total Current Liabilities is an item on Theravance Biopharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Theravance Biopharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Theravance Biopharma's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Theravance Biopharma's overall financial position and show how it may be relating to other accounts over time.
Total Current Liabilities10 Years Trend
Pretty Stable
   Total Current Liabilities   
       Timeline  

Theravance Total Current Liabilities Regression Statistics

Arithmetic Mean51,789,377
Geometric Mean43,361,827
Coefficient Of Variation65.36
Mean Deviation26,136,016
Median41,256,000
Standard Deviation33,850,268
Sample Variance1145.8T
Range100.9M
R-Value0.26
Mean Square Error1148.9T
R-Squared0.07
Significance0.34
Slope1,987,195
Total Sum of Squares16041.8T

Theravance Total Current Liabilities History

202423.5 M
202324.8 M
202228.7 M
202158.6 M
2020123.6 M
2019111.7 M
201898.6 M

About Theravance Biopharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Theravance Biopharma income statement, its balance sheet, and the statement of cash flows. Theravance Biopharma investors use historical funamental indicators, such as Theravance Biopharma's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Theravance Biopharma investors may use each financial statement separately, they are all related. The changes in Theravance Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Theravance Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Theravance Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Theravance Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Current Liabilities24.8 M23.5 M

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Theravance Stock

When determining whether Theravance Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theravance Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theravance Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theravance Biopharma Stock:
Check out the analysis of Theravance Biopharma Correlation against competitors.
For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.89)
Revenue Per Share
1.191
Quarterly Revenue Growth
0.392
Return On Assets
(0.06)
Return On Equity
(0.16)
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.